Volume 9, Number 1—January 2003
Perspective
Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors
W. Michael Scheld*
Table 1
Comparison of in vitro activitya of four fluoroquinolones against a range of pathogensb
| Fluoroquinolone | E. coli | P. aeruginosa | K. pneumoniae | S. pneumoniaec | S. aureusd | Ref. | |
|---|---|---|---|---|---|---|---|
| Ciprofloxacin |
0.03 |
8 |
NR |
4 |
0.5 |
12 |
|
| 0.125–0.5 |
0.25–4 |
0.25 |
1-2 |
0.5–1 |
13 |
||
| 0.016 |
8 |
0.06 |
4 |
0.5 |
14 |
||
| 0.016 |
2 |
0.25 |
2 |
0.5 |
15 |
||
| 0.25 |
4 |
0.06 |
2 |
1 |
16 |
||
| Levofloxacin |
NR |
32 |
NR |
2 |
0.25 |
12 |
|
| 0.06–<0.5 |
0.5–>4 |
0.12–0.25 |
1–2 |
0.25 |
13 |
||
| 0.03 |
32 |
0.13 |
2 |
0.25 |
14 |
||
| 0.06 |
4 |
0.25 |
2 |
0.25 |
15 |
||
| 0.12 |
16 |
0.12 |
1 |
0.5 |
16 |
||
| Moxifloxacin |
0.06 |
8 |
NR |
0.25 |
0.06 |
12 |
|
| 0.06–1 |
8 |
0.12–0.25 |
0.06–0.25 |
0.12 |
13 |
||
| 0.008 |
32 |
0.13 |
0.25 |
0.06 |
14 |
||
| 0.06 |
8 |
0.5 |
0.25 |
0.06 |
15 |
||
| 0.5 |
8 |
0.5 |
0.25 |
0.12 |
16 |
||
| Gatifloxacin |
NR |
32 |
NR |
1.0 |
0.125 |
12 |
|
| 0.06 |
>4 |
0.06–0.25 |
0.5 |
0.12 |
13 |
||
| 0.016 |
32 |
0.13 |
1 |
0.13 |
14 |
||
| 0.1 | 8 | 0.12 | 0.5 | 0.12 | 15 | ||
aMIC90 reported.
bE. coli, Escherichia coli; P. aeruginosa, Pseudomonas aeruginosa; K. pneumoniae, Klebsiella pneumoniae; S. pneumoniae, Streptococcus pneumoniae; S. aureus, Staphylococcus aureus; NR, not reported.
cPenicillin-susceptible S. pneumoniae, except in the case of Reference 12, which did not specify.
dMethicillin-susceptible S. aureus, except in the case of Reference 12, which did not specify.
